ES2530670T3 - Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo - Google Patents

Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo Download PDF

Info

Publication number
ES2530670T3
ES2530670T3 ES08711707T ES08711707T ES2530670T3 ES 2530670 T3 ES2530670 T3 ES 2530670T3 ES 08711707 T ES08711707 T ES 08711707T ES 08711707 T ES08711707 T ES 08711707T ES 2530670 T3 ES2530670 T3 ES 2530670T3
Authority
ES
Spain
Prior art keywords
same
pharmaceutical composition
amino acid
acid sequence
fgf23 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08711707T
Other languages
English (en)
Inventor
Yuji Yamazaki
Itaru Urakawa
Hitoshi Yoshida
Yukiko Aono
Takeyoshi Yamashita
Takashi Shimada
Hisashi Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2530670(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ES2530670T3 publication Critical patent/ES2530670T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)

Abstract

Anticuerpo frente a FGF23 humano o un fragmento funcional del mismo frente a FGF23 humano, que comprende una secuencia de aminoácidos de cadena pesada que comprende una secuencia de aminoácidos desde Q en la posición 20 hasta S en la posición 136 de SEC ID Nº 12 y una secuencia de aminoácidos de cadena ligera que comprende una secuencia de aminoácidos desde A en la posición 23 hasta K en la posición 128 de SEC ID Nº 14.
ES08711707T 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo Active ES2530670T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007034018 2007-02-14
PCT/JP2008/052918 WO2008099969A1 (ja) 2007-02-14 2008-02-14 抗fgf23抗体及びそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
ES2530670T3 true ES2530670T3 (es) 2015-03-04

Family

ID=39690189

Family Applications (3)

Application Number Title Priority Date Filing Date
ES12170984T Active ES2625823T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES17152168T Active ES2811318T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES08711707T Active ES2530670T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES12170984T Active ES2625823T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES17152168T Active ES2811318T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo

Country Status (23)

Country Link
US (4) US7883705B2 (es)
EP (3) EP2502996B1 (es)
JP (1) JP4800396B2 (es)
KR (1) KR101462291B1 (es)
CN (2) CN102702355B (es)
AU (1) AU2008215346B2 (es)
CA (1) CA2677782C (es)
CY (3) CY1118835T1 (es)
DK (3) DK2128253T3 (es)
ES (3) ES2625823T3 (es)
FR (1) FR18C1032I2 (es)
HK (2) HK1140228A1 (es)
HR (2) HRP20170548T1 (es)
HU (3) HUE031728T2 (es)
LT (3) LT3181691T (es)
LU (2) LUC00082I2 (es)
NL (1) NL300945I2 (es)
NO (1) NO2018025I1 (es)
PL (3) PL3181691T3 (es)
PT (3) PT3181691T (es)
SI (2) SI3181691T1 (es)
TW (1) TWI422593B (es)
WO (1) WO2008099969A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4799801B2 (ja) * 2000-08-11 2011-10-26 協和発酵キリン株式会社 リン酸代謝、カルシウム代謝、石灰化及びビタミンｄ代謝を調節するポリペプチド並びにそれをコードするｄｎａ
CA2471656C (en) * 2001-12-28 2012-07-31 Kirin Beer Kabushiki Kaisha Antibody against fibroblast growth factor-23
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
US20140294820A1 (en) 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
SI3151859T1 (sl) * 2014-06-09 2021-06-30 Ultragenyx Pharmaceutical Inc. Uspešen in učinkovit nadzor serumskega fosfata za optimalno tvorbo kosti
WO2018069232A1 (en) 2016-10-10 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of having cardiac hypertrophy
WO2018181935A1 (ja) 2017-03-30 2018-10-04 シスメックス株式会社 抗ＡｐｏＡ１抗体
AU2020253833A1 (en) * 2019-03-29 2021-10-28 Atarga, Llc Anti FGF23 antibody
WO2024034638A1 (ja) * 2022-08-10 2024-02-15 協和キリン株式会社 抗ｆｇｆ２３抗体又は該抗体断片

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
WO1985003934A1 (en) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61178926U (es) 1985-04-23 1986-11-08
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
MXPA00011272A (es) 1998-05-18 2003-04-22 Univ London Una novedosa fosfatonina de hormona polipeptida.
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
WO2000060085A1 (en) 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US6596849B1 (en) * 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2492070A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Lung tumor marker pro4329 polypeptides and nucleic acids encoding the same
JP2003516150A (ja) 1999-12-08 2003-05-13 ジェンセット 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ
WO2001049740A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf12
JP2003523190A (ja) 2000-02-14 2003-08-05 スミスクライン・ビーチャム・コーポレイション 新規化合物
AU3976701A (en) 2000-02-15 2001-08-27 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
AU2001245535A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
US20020082205A1 (en) 2000-03-08 2002-06-27 Nobuyuki Itoh Human FGF-23 gene and gene expression products
US7223563B2 (en) 2000-07-19 2007-05-29 Advanced Research And Technology Institute Fibroblast growth factor (FGF23) nucleic acids
JP4799801B2 (ja) * 2000-08-11 2011-10-26 協和発酵キリン株式会社 リン酸代謝、カルシウム代謝、石灰化及びビタミンｄ代謝を調節するポリペプチド並びにそれをコードするｄｎａ
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
WO2002076467A1 (en) 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism
JP2004527253A (ja) * 2001-04-26 2004-09-09 ジーンプロット・インコーポレイテッド 線維芽細胞成長因子−２３分子およびその使用
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
CA2471656C (en) 2001-12-28 2012-07-31 Kirin Beer Kabushiki Kaisha Antibody against fibroblast growth factor-23
US7094551B2 (en) * 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
US20070036734A1 (en) * 2003-03-17 2007-02-15 Kirin Beer Kabushiki Kaisha Therapeutic agent for periodontal disease
MXPA06014075A (es) * 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
MX2007001470A (es) * 2004-08-05 2007-03-26 Genentech Inc Antagonistas anti-cmet humanizados.
CN101010427B (zh) * 2004-09-06 2011-07-27 协和发酵麒麟株式会社 抗a33抗体
US20090151011A1 (en) 2005-01-21 2009-06-11 Kirin Pharma Kabushiki Kaisha Chimeric Non-Human Animal and Use Thereof
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
US20100062984A1 (en) * 2007-01-25 2010-03-11 Rajiv Kumar Fgf-23 polypeptides
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
KR20090114452A (ko) 2009-11-03
DK2502996T3 (en) 2017-05-08
LT2502996T (lt) 2017-06-26
LTC2502996I2 (lt) 2019-05-10
PL2128253T3 (pl) 2015-04-30
NL300945I2 (en) 2020-05-13
CN102702355B (zh) 2014-09-24
CN102702355A (zh) 2012-10-03
AU2008215346A1 (en) 2008-08-21
US20090148461A1 (en) 2009-06-11
LUC00081I2 (es) 2018-10-01
DK2128253T3 (en) 2015-01-05
SI3181691T1 (sl) 2020-09-30
HK1140228A1 (en) 2010-10-08
SI2502996T1 (sl) 2017-08-31
US20190106485A1 (en) 2019-04-11
AU2008215346B2 (en) 2013-01-10
CY2018021I1 (el) 2019-07-10
DK3181691T3 (da) 2020-08-17
US20110182913A1 (en) 2011-07-28
EP2502996A2 (en) 2012-09-26
CN101652476B (zh) 2012-07-04
LUC00082I2 (es) 2018-10-01
US20160159895A1 (en) 2016-06-09
EP3181691A1 (en) 2017-06-21
PL3181691T3 (pl) 2020-11-02
EP2502996A3 (en) 2013-04-10
KR101462291B1 (ko) 2014-11-14
US7883705B2 (en) 2011-02-08
HRP20201266T1 (hr) 2021-02-05
WO2008099969A1 (ja) 2008-08-21
JP4800396B2 (ja) 2011-10-26
HUS1800034I1 (hu) 2018-09-28
HUE031728T2 (en) 2017-07-28
TWI422593B (zh) 2014-01-11
CY1118835T1 (el) 2018-01-10
CY2018021I2 (el) 2019-07-10
PT2128253E (pt) 2015-02-04
HUE050517T2 (hu) 2020-12-28
HRP20170548T1 (hr) 2017-08-25
HK1172917A1 (en) 2013-05-03
EP2128253A4 (en) 2010-03-10
JPWO2008099969A1 (ja) 2010-05-27
TW200902549A (en) 2009-01-16
EP2502996B1 (en) 2017-03-29
CY1123240T1 (el) 2021-10-29
CA2677782A1 (en) 2008-08-21
NL300945I1 (en) 2018-08-15
FR18C1032I1 (es) 2018-08-31
US10202446B2 (en) 2019-02-12
PT2502996T (pt) 2017-05-10
US9290569B2 (en) 2016-03-22
LT3181691T (lt) 2020-08-25
EP2128253A1 (en) 2009-12-02
EP3181691B1 (en) 2020-07-15
NO2018025I1 (no) 2018-08-09
FR18C1032I2 (fr) 2019-08-09
CA2677782C (en) 2016-07-26
LTPA2018508I1 (lt) 2018-09-10
PL2502996T3 (pl) 2017-07-31
PT3181691T (pt) 2020-08-26
CN101652476A (zh) 2010-02-17
ES2811318T3 (es) 2021-03-11
EP2128253B1 (en) 2014-12-03
ES2625823T3 (es) 2017-07-20

Similar Documents

Publication Publication Date Title
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
PE20120429A1 (es) Proteinas de enlace de miostatina
ES2585480T3 (es) Anticuerpo anti-NR10 y uso del mismo
CY1120137T1 (el) Ενεσιμα σκευασματα βοτουλινικης τοξινης
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
NL301089I2 (nl) imlifidase
PE20121393A1 (es) Analogo peptidico de oxintomodulina
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
ES2531385T3 (es) Formulación que comprende un anticuerpo contra la selectina P
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
PH12013502192A1 (en) Antibodies against human angiopoietin 2
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
ATE497975T1 (de) Il-21-varianten
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
EA201001322A1 (ru) Вакцины против хламидиоза
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
CO6331346A2 (es) Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
PA8852901A1 (es) Inhibidores de proteina cinasa
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.